TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Down 25.0 %

Shares of TCON opened at $0.04 on Tuesday. The company has a 50 day moving average of $0.10 and a two-hundred day moving average of $0.72. TRACON Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $14.75. The company has a market cap of $136,400.00, a price-to-earnings ratio of 0.01 and a beta of 1.43.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The firm had revenue of $0.06 million during the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.